Q-omics provides the consensus-scored TSSK1B profile across patient tissues and cancer cell-line models. TSSK1B expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, TSSK1B is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, TSSK1B RNA expression shows 6,558 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ESCA, LUSC, and STAD as cancer lineages where TSSK1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSSK1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSSK1B survival associations across molecular data types. TSSK1B RNA expression shows survival associations in the most cancer types (16), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSSK1B RNA expression–survival associations across cancer types. High TSSK1B expression shows unfavorable associations in KIRC, CHOL, STAD, KICH and OV, but favorable associations in ESCA. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify ESCA as the clearest survival context for TSSK1B RNA expression.
This table summarizes TSSK1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for TSSK1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSSK1B shows higher tumor expression in LUSC. The LUSC box plot shows higher TSSK1B RNA expression in tumor versus normal tissue (log2 FC = +0.008, t-test p = .006).
This table shows molecular features associated with TSSK1B in patient tissues and cancer cell lines. In patient samples, TSSK1B shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, TSSK1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
